Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis

  title={Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF-$\kappa$B-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis},
  author={Ju Won Park and Eunkyung Bae and Chansu Lee and Jee Hye Choi and Woo June Jung and Kwang Sung Ahn and Sung-Soo Yoon},
  journal={BMB Reports},
  pages={274 - 279}
Bortezomib has been known as the most promising anti-cancer drug for multiple myeloma (MM). However, recent studies reported that not all MM patients respond to bortezomib. To overcome such a stumbling-block, studies are needed to clarify the mechanisms of bortezomib resistance. In this study, we established a bortezomib-resistant cell line (U266/velR), and explored its biological characteristics. The U266/velR showed reduced sensitivity to bortezomib, and also showed crossresistance to the… 

Figures from this paper

KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
It is reported that SB743921 induces mitochondria-mediated cell death via inhibition of the NF-κB signaling pathway, but does not cause cell cycle arrest in KMS20 MM cells, and combined treatment with bortezomib induces death in bortzomib-resistant K MS20 cells.
Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma
This study shows that the combination of proteasome and HSP70 inhibitors induced cell death in tumor cells in vitro (late apoptosis induction) and in vivo (inhibition of tumor growth) with special benefit in U266-LUC-PURO, bearing 17p deletion.
Characterization of multidrug‑resistant osteosarcoma sublines and the molecular mechanisms of resistance.
It is demonstrated that the molecular alterations of drug resistance may change with the degree of drug resistant cells, and the intratumor clonal and phenotypic heterogeneity may be responsible for drug resistance.
MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma
It is demonstrated that MTI-101 is synergistic when combined with bortezomib, using both myeloma cell lines and primary myel cancer patient specimens, suggesting that relapse may occur at a cost for increased sensitivity to Ca2+ overload mediated cell death.
E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential
The role of E3s in cancer drug resistance from the perspective of drug class is summarized and it is suggested that E 3s could be desirable drug targets.
Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
In vitro results provide additional evidence that combinations of protein homeostasis inhibitors might be explored as treatment options for MM and suggest that it is acting as a compensatory mechanism in an attempt of the cell to handle the otherwise lethal large amount of immunoglobulin overload.
Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review
The development of chemoresistant cells lines are presented as a model in experimental oncology to present the acquisition of drug resistance in antineoplastic treatment and it has been observed that the drugs used for induction of resistance represented the Drugs used for first-line treatment of each neoplasia.
Aloe-Emodin Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Colorectal Cancer Cells
  • Chun-Mao Cheng, W. Dong
  • Biology, Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2018
AE might serve as a candidate in the treatment of colorectal cancer through inducing ER stress-dependent apoptosis through inducing endoplasmic reticulum (ER) stress.


Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
A novel mechanism of bortezomib resistance associated with the selective overexpression of a mutant PSMB5 protein is established and is established in human myelomonocytic THP1 cells by exposure to stepwise increasing concentrations of bortsomib.
Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells
These findings show that primary MM cells frequently harbor PIR NF-κB activity that is further enhanced by the presence of patient-derived BMSCs, and suggest that this activity is likely relevant to the drug resistance development in some patients.
Simultaneous inhibition of the constitutively activated nuclear factor κB and of the Interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells
Combined targeting of NF-κB κB and STAT3 signaling pathways was the most effective treatment in inducing apoptosis and warrants further investigations in other apoptosis resistant MM cell lines as well as in suitable MM animal models.
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells
The data showed that the inhibition of NF-κB activation abrogated MM cell proliferation induced by the IL-6 pathway, and might represent a promising therapeutic strategy for the treatment of MM.
Discovery, Development, and clinical applications of bortezomib.
Evidence suggests that certain prognostic factors, such as older age and bone marrow containing more than 50% plasma cells, may be useful in predicting response and survival time in multiple myeloma patients receiving bortezomib.
Induction of Drug Resistance in Human Rhabdomyosarcoma Cell Lines Is Associated with Increased Maturation: Possible Explanation for Differentiation in Recurrences?
  • I. Leuschner, T. Heuer, D. Harms
  • Biology
    Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • 2002
It is concluded that chemotherapy-induced differentiation in vivo might be a morphological sign of chemoresistance in rhabdomyosarcoma.
Proteasome inhibition in cancer: development of PS-341.
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Enhanced understanding of the functional importance of the MM BM microenvironment and its inter-relation with the MM cell resulting in homing, seeding, proliferation and survival, new molecular targets have been identified and derived treatment regimens in MM have already changed fundamentally during recent years.
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells
Increased expression, altered subunit composition and increased activity of proteasomes constitute a hitherto unknown adaptive and autoregulatory feedback mechanism to allow cells to survive the lethal challenge of prote asome inhibition and to establish a hyperproliferative and apoptosis‐resistant phenotype.
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
These studies demonstrate a novel mechanism of action for lenalidomide, namely targeting SP fraction, providing the framework for new therapeutic strategies targeting subpopulations of MM cells including presumptive stem cells.